Market Overview

UPDATE: MLV & Co Upgrades XOMA on Valuation

Related XOMA
Earnings Scheduled For March 9, 2016
Every Biotech Catalyst Wedbush Is Watching In 2016
Buy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital Hyperinsulinism And Refractory Prolactinoma (Seeking Alpha)

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh upgraded the rating on XOMA (NASDAQ: XOMA) from Hold to Buy, and reiterated the $7.00 price target.

In the report, MLV & Co noted, “We now upgrade shares of XOMA. Our call is based on 1) valuation and 2) optimism around positive upcoming data from the P3 EYEGUARD-B trial in Behcet's uveitis (an orphan eye condition) for lead asset gevokizumab (gevo) expected sometime mid-year. On positive data, we're expecting ~15-20% of upside to the stock, with potential for add'l upside in the form of two other P3 readouts for gevo expected by year-end (from the EYEGUARD-A/C trials), we feel comfortable taking XOMA now back up to Buy, while maintaining our 1-yr $7 PT.”

XOMA closed on Monday at $3.82.

Latest Ratings for XOMA

Jul 2015JefferiesDowngradesBuyHold
Jun 2015SusquehannaDowngradesPositiveNeutral
May 2015Credit SuisseAssumesNeutral

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: Graig C. Suvannavejh MLV & CoAnalyst Color Upgrades Analyst Ratings


Related Articles (XOMA)

View Comments and Join the Discussion!